==========================================================================================
MEDIKAMENT 1: Erlotinib (EGFR Tyrosine Kinase Inhibitor)
==========================================================================================

Erwartete Biomarker:
  Primary: MUT__EGFR (aktivierende Mutationen → Sensitivität)
  Secondary: CNV__EGFR, TPM__EGFR (Amplifikation/Expression)
  Resistance: MUT__KRAS, MUT__BRAF (downstream activation)
  Bypass: TPM__MET, CNV__MET (alternative signaling)

Testing unimodality for all features...

Generating 200 complementary pairs...

Running CPSS with B=200 pairs...
  Using q_rf=19 (reduced from q=96 to satisfy θ ≤ 1/√3)

CPSS Results:
  Features (d): 489
  Target q: 96
  Observed q̂: 19.0
  θ (q̂/d): 0.0389
  Worst-case τ*: 0.515
  Features passing worst-case: 7
  Features passing unimodal: 0

------------------------------------------------------------------------------------------
Top 15 Features:
------------------------------------------------------------------------------------------
  336. METH__STRAP                         Score=0.998
  98. METH__MPHOSPH9                      Score=0.897
  457. METH__FASN                          Score=0.805
  418. METH__RASA2                         Score=0.700
  67. METH__GPR108                        Score=0.667
  282. CNV__CCDC6                          Score=0.595
  219. CNV__PAX3                           Score=0.520
  343. MUT__NFE2L2                         Score=0.482
  118. CNV__NCOA4                          Score=0.465
  261. MUT__NOTCH1                         Score=0.455
  223. CNV__KAT6B                          Score=0.425
  347. CNV__MPL                            Score=0.422
  198. METH__FOXO3                         Score=0.405
  290. CNV__FLI1                           Score=0.395
  489. MUT__NRAS                           Score=0.390

------------------------------------------------------------------------------------------
Biomarker Validierung:
------------------------------------------------------------------------------------------
✗  MUT__EGFR            NOT FOUND - EGFR mutations (primary)
✗  CNV__EGFR            NOT FOUND - EGFR amplification
✗  TPM__EGFR            NOT FOUND - EGFR expression
✗  MUT__KRAS            NOT FOUND - KRAS resistance
✗  MUT__BRAF            NOT FOUND - BRAF resistance
✗  TPM__MET             NOT FOUND - MET bypass
✗  CNV__MET             NOT FOUND - MET amplification

Stark gefunden: 0/7



==========================================================================================
MEDIKAMENT 2: Cisplatin (DNA Cross-Linking Agent)
==========================================================================================

Erwartete Biomarker:
  DNA Repair: MUT__TP53, MUT__ERCC1, MUT__ERCC2 (NER pathway)
  MMR: MUT__MSH2, MUT__MLH1 (Mismatch repair)
  HR: MUT__BRCA1, MUT__BRCA2 (Homologous recombination)
  Resistance: MUT__KRAS

Testing unimodality for all features...

Generating 200 complementary pairs...

Running CPSS with B=200 pairs...
  Using q_rf=16 (reduced from q=80 to satisfy θ ≤ 1/√3)

CPSS Results:
  Features (d): 410
  Target q: 80
  Observed q̂: 16.0
  θ (q̂/d): 0.0390
  Worst-case τ*: 0.516
  Features passing worst-case: 16
  Features passing unimodal: 2

------------------------------------------------------------------------------------------
Top 15 Features:
------------------------------------------------------------------------------------------
  128. TPM__PDE1B                          Score=1.000
  288. CNV__NFATC2                         Score=1.000
  17. TPM__IKZF1                          Score=1.000
   8. METH__DSTN                          Score=1.000
  16. TPM__TM4SF1-AS1                     Score=1.000
  316. CNV__ZNF780A                        Score=0.965
  367. CNV__KAT6B                          Score=0.963
✓ 166. MUT__KRAS                           Score=0.912
  388. CNV__TET1                           Score=0.802
  116. CNV__TCF7L2                         Score=0.780
  121. MUT__STAG2                          Score=0.677
  383. CNV__RAP1GDS1                       Score=0.625
  42. CNV__SUFU                           Score=0.608
  238. CNV__FAS                            Score=0.568
  83. CNV__PRF1                           Score=0.565

------------------------------------------------------------------------------------------
Biomarker Validierung:
------------------------------------------------------------------------------------------
✗  MUT__TP53            NOT FOUND - TP53 (apoptosis)
✗  MUT__ERCC1           NOT FOUND - ERCC1 (NER)
~  MUT__ERCC2           Rank 158, Score 0.000 - ERCC2 (NER helicase) (zu schwach)
✗  MUT__MSH2            NOT FOUND - MSH2 (MMR)
~  MUT__MLH1            Rank  88, Score 0.003 - MLH1 (MMR) (zu schwach)
✗  MUT__BRCA1           NOT FOUND - BRCA1 (HR)
~  MUT__BRCA2           Rank 402, Score 0.000 - BRCA2 (HR) (zu schwach)
✓✓ MUT__KRAS            Rank 166, Score 0.912 - KRAS (resistance)

Stark gefunden: 1/8



==========================================================================================
MEDIKAMENT 3: Dabrafenib (BRAF V600E Inhibitor)
==========================================================================================

Erwartete Biomarker:
  Primary: MUT__BRAF (V600E Mutation → high sensitivity)
  Pathway: MUT__NRAS, MUT__KRAS (MAPK pathway)
  Expression: TPM__BRAF

Testing unimodality for all features...

Generating 200 complementary pairs...

Running CPSS with B=200 pairs...
  Using q_rf=19 (reduced from q=96 to satisfy θ ≤ 1/√3)

CPSS Results:
  Features (d): 489
  Target q: 96
  Observed q̂: 19.0
  θ (q̂/d): 0.0389
  Worst-case τ*: 0.515
  Features passing worst-case: 18
  Features passing unimodal: 2

------------------------------------------------------------------------------------------
Top 15 Features:
------------------------------------------------------------------------------------------
✓  1. MUT__BRAF                           Score=1.000
  378. METH__WDR81                         Score=1.000
  40. METH__HNRPLL                        Score=1.000
  476. METH__EGFL8                         Score=1.000
   2. METH__CCM2                          Score=0.995
  204. METH__CD3EAP                        Score=0.985
  42. TPM__MIR142HG                       Score=0.978
  43. METH__EVL                           Score=0.975
  290. METH__MRPS18B                       Score=0.968
  123. TPM__IKZF1                          Score=0.958
  353. TPM__PIK3CG                         Score=0.955
  479. METH__RINL                          Score=0.917
  177. METH__BIN2                          Score=0.910
  112. METH__TMEM199                       Score=0.890
  30. METH__LOC25845                      Score=0.890

------------------------------------------------------------------------------------------
Biomarker Validierung:
------------------------------------------------------------------------------------------
✓✓ MUT__BRAF            Rank   1, Score 1.000 - BRAF V600E (primary target)
✗  MUT__NRAS            NOT FOUND - NRAS (MAPK pathway)
~  MUT__KRAS            Rank  38, Score 0.000 - KRAS (MAPK pathway) (zu schwach)
✗  TPM__BRAF            NOT FOUND - BRAF expression

Stark gefunden: 1/4



==========================================================================================
GESAMT-ZUSAMMENFASSUNG: RF-CPSS Performance
==========================================================================================
Erlotinib      : 0/7 Biomarker gefunden (0.0%)
Cisplatin      : 1/8 Biomarker gefunden (12.5%)
Dabrafenib     : 1/4 Biomarker gefunden (25.0%)

GESAMT         : 2/19 Biomarker gefunden (10.5%)

==========================================================================================
✗ RF-CPSS unzureichend: Weniger als 25% der Biomarker gefunden
==========================================================================================
